Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2016 2
2017 1
2019 3
2020 3
2021 4
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity.
Zhang Z, Luo L, Xing C, Chen Y, Xu P, Li M, Zeng L, Li C, Ghosh S, Della Manna D, Townes T, Britt WJ, Wajapeyee N, Sleckman BP, Chong Z, Leavenworth JW, Yang ES. Zhang Z, et al. Among authors: della manna d. Nat Cancer. 2021 Oct;2(10):1018-1038. doi: 10.1038/s43018-021-00263-z. Epub 2021 Oct 22. Nat Cancer. 2021. PMID: 35121884 Free PMC article.
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES. Stringer-Reasor EM, et al. Among authors: della manna dl. Breast Cancer Res. 2021 Mar 4;23(1):30. doi: 10.1186/s13058-021-01408-9. Breast Cancer Res. 2021. PMID: 33663560 Free PMC article. Clinical Trial.
18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition.
Reeves KM, Song PN, Angermeier A, Della Manna D, Li Y, Wang J, Yang ES, Sorace AG, Larimer BM. Reeves KM, et al. Among authors: della manna d. Clin Cancer Res. 2022 Jan 15;28(2):327-337. doi: 10.1158/1078-0432.CCR-21-2394. Epub 2021 Oct 6. Clin Cancer Res. 2022. PMID: 34615724 Free PMC article.
Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression.
Chandrashekar DS, Chakravarthi BVSK, Robinson AD, Anderson JC, Agarwal S, Balasubramanya SAH, Eich ML, Bajpai AK, Davuluri S, Guru MS, Guru AS, Naik G, Della Manna DL, Acharya KK, Carskadon S, Manne U, Crossman DK, Ferguson JE, Grizzle WE, Palanisamy N, Willey CD, Crowley MR, Netto GJ, Yang ES, Varambally S, Sonpavde G. Chandrashekar DS, et al. Among authors: della manna dl. Oncogene. 2020 May;39(20):4077-4091. doi: 10.1038/s41388-020-1275-7. Epub 2020 Mar 30. Oncogene. 2020. PMID: 32231273
Randomized trial of weight loss in primary breast cancer: Impact on body composition, circulating biomarkers and tumor characteristics.
Demark-Wahnefried W, Rogers LQ, Gibson JT, Harada S, Frugé AD, Oster RA, Grizzle WE, Norian LA, Yang ES, Della Manna D, Jones LW, Azrad M, Krontiras H. Demark-Wahnefried W, et al. Among authors: della manna d. Int J Cancer. 2020 May 15;146(10):2784-2796. doi: 10.1002/ijc.32637. Epub 2019 Sep 5. Int J Cancer. 2020. PMID: 31442303 Free PMC article. Clinical Trial.
14 results